Intensity Therapeutics presents promising Phase 2 data for INT230-6 in Triple Negative Breast Cancer at SABCS 2024.
Read more
FDA approves Crenessity for Congenital Adrenal Hyperplasia, reducing glucocorticoid dose in adults and children.
Read more
MannKind's Afrezza shows non-inferiority to injections in Phase 3 trial for Pediatric Diabetes.
Read more
HUTCHMED's ORPATHYS® and TAGRISSO® combo receives Breakthrough Therapy Designation in China for EGFR mutation-positive NSCLC with MET amplification.
Read more
Sinovac begins Phase III trial for bivalent vaccine against Hand, Foot, and Mouth Disease in children.
Read more
SK Biopharmaceuticals partners with ProEn Therapeutics to develop radiopharmaceuticals for oncology by 2027.
Read more
FDA grants Breakthrough Device Designation to MeMed Severity test for suspected Sepsis management.
Read more
Agendia's MammaPrint and BluePrint predict chemotherapy response and CDK4/6 resistance in early-stage Breast Neoplasms.
Read more
Jazz Pharmaceuticals announces CEO Bruce Cozadd's retirement plan, with a successor search to conclude by 2025.
Read more
Global hematology market projected to grow at 8% CAGR by 2030, driven by blood disorder prevalence and technological advancements.
Read more
Vir Biotechnology's tobevibart and elebsiran receive FDA and EMA designations for Chronic Hepatitis Delta treatment.
Read more
Promise Bio secures $8.3M to advance precision medicine for immune-mediated diseases using AI and epiproteomics.
Read more
Merck discontinues vibostolimab and favezelimab trials for Non-Small Cell Lung Cancer and Hodgkin Lymphoma due to futility.
Read more
Bio-Thera Solutions expands LATAM partnership with SteinCares, adding a third biosimilar for distribution in Brazil and LATAM.
Read more
FDA approves CRENESSITY for Classic Congenital Adrenal Hyperplasia, offering a new treatment option after 70 years.
Read more
Bausch + Lomb acquires Elios Vision, enhancing minimally invasive glaucoma surgery capabilities with ELIOS laser technology.
Read more
Candid Therapeutics announces three new collaborations to develop T-cell engager antibodies for autoimmune diseases.
Read more
FDA approves Crenessity for Congenital Adrenal Hyperplasia, reducing glucocorticoid dose in adults and children.
Read more
Merus doses first patient in Phase 2 trial of petosemtamab for metastatic colorectal cancer.
Read more
GXP-Storage receives investment from Whistler Capital to expand biorepository and regulated material management services.
Read more
Contineum Therapeutics begins Phase 1b trial of PIPE-791 for Idiopathic Pulmonary Fibrosis and Progressive Multiple Sclerosis.
Read more
Menarini's Obicetrapib shows significant LDL-C reduction in Phase 3 trials for Atherosclerotic Cardiovascular Disease and Familial Hypercholesterolemia.
Read more
Adcendo exercises option to use Biocytogen's antibodies, advancing ADC development for cancer treatment.
Read more
Immutep reveals LAG-3 binding mechanism to MHC Class II, advancing cancer and autoimmune therapy development.
Read more
FDA approves VTAMA cream for Atopic Dermatitis in patients aged 2 and older.
Read more
